PHESGO 600-600

Indications

• Adjuvant treatment of HER2-positive early stage breast cancer
• Neoadjuvant treatment of HER2-positive locally advanced breast cancer in combination with trastuzumab and chemotherapy
• Treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer in combination with trastuzumab and docetaxel

Dosage

Children: Refer to the BNF for Children for dosing information.

Adults: Refer to product literature or local protocols for dosing information.

Mechanism of action

Pertuzumab is a monoclonal antibody that binds to the extracellular domain II of the HER2 receptor. This binding prevents HER2 from dimerizing with other members of the HER family, which is crucial for signal transduction pathways that promote cell proliferation and survival. By inhibiting these pathways, pertuzumab effectively reduces the growth and spread of HER2-positive tumors.

Pharmacodynamics

Pertuzumab exhibits dose-dependent inhibition of HER2 signaling pathways, leading to decreased cell proliferation and increased apoptosis in HER2-overexpressing tumor cells. Its efficacy is enhanced when used in combination with trastuzumab, as both agents target HER2 through different mechanisms.

Pharmacokinetics

Pertuzumab is administered via intravenous infusion, with a half-life of approximately 18 days. It demonstrates linear pharmacokinetics within the therapeutic dose range. The drug is primarily eliminated by protein catabolism. Its volume of distribution is about 7.5 L, and it is not significantly metabolized by cytochrome P450 enzymes, making it less prone to drug-drug interactions.

Contra-indications

• History of congestive heart failure
• Impaired left ventricular function
• Recent myocardial infarction
• Severe cardiac arrhythmia
• Uncontrolled hypertension

Adverse effects

• Alopecia
• Anaemia
• Appetite decrease
• Fatigue
• Insomnia
• Left ventricular dysfunction
• Leucopenia
• Mucositis
• Myalgia
• Nail disorder
• Nausea
• Neutropenia
• Oedema
• Pain
• Peripheral neuropathy
• Respiratory disorders
• Skin reactions
• Stomatitis
• Taste alteration
• Vomiting

Interactions

• Monoclonal antibodies may interact with other immunotherapies
• Consult Appendix 1 for detailed interactions

Precautions

• Conditions that could impair left ventricular function
• Caution in patients with a history of anthracycline exposure
• Caution in patients with previous radiotherapy to the chest area

Pregnancy

Avoid use during pregnancy due to potential toxicity and teratogenic effects observed in animal studies.

Breast-feeding

Avoid; no information available on the safety of pertuzumab during breastfeeding.

Storage

Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light.

Formulations

• Pertuzumab (Perjeta®) 420 mg/14 ml concentrate for solution for infusion vials

Indications

• Metastatic breast cancer in patients with HER2 overexpression who have received at least two prior chemotherapy regimens, including an anthracycline and a taxane.
• Metastatic gastric cancer in patients with HER2-positive tumors who have not received prior treatment for this condition.

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines in paediatric patients, as specific doses are not provided in the BNF.

Adults: The recommended dosage for adults is typically 8 mg/kg as a loading dose, followed by 6 mg/kg every three weeks, administered via intravenous infusion or subcutaneous injection.

Mechanism of action

Trastuzumab binds specifically to the extracellular domain of the human epidermal growth factor receptor 2 (HER2), leading to inhibition of HER2-mediated signaling pathways, including the PI3K/AKT and MAPK pathways. This blockade reduces cell proliferation and induces apoptosis in HER2-overexpressing cells. Additionally, trastuzumab enhances antibody-dependent cellular cytotoxicity (ADCC) through immune effector cells.

Pharmacodynamics

Trastuzumab demonstrates a dose-dependent effect on inhibiting the growth of HER2-positive cancer cells. Its clinical efficacy is primarily associated with its ability to target HER2 overexpression, leading to decreased tumor growth and improved survival rates in patients with HER2-positive breast and gastric cancers. Common side effects include infusion-related reactions, gastrointestinal disturbances, and increased risk of infections.

Pharmacokinetics

Trastuzumab has a terminal half-life of approximately 5 to 8 days after the initial intravenous administration. It is distributed widely, with a volume of distribution typically around 2-3 L/kg. Metabolism occurs via proteolytic degradation, primarily in the reticuloendothelial system. The clearance is affected by the patient's body size and HER2 expression levels, and it is excreted mainly through the lymphatic system.

Contra-indications

• Severe dyspnoea at rest
• Symptomatic heart failure
• Uncontrolled arrhythmias

Adverse effects

• Abdominal pain
• Alopecia
• Anaemia
• Appetite decreased
• Arthralgia
• Asthenia
• Constipation
• Cough exacerbated
• Decreased leucocytes
• Diarrhoea
• Dyspnoea
• Electrolyte imbalance
• Fever
• Headache
• Hyperbilirubinaemia
• Hyperhidrosis
• Hypogammaglobulinaemia
• Increased risk of infection
• Infusion related reaction
• Malaise
• Mucositis
• Muscle spasms
• Nasal congestion
• Nausea
• Neutropenia
• Pain
• Paresthesia
• Peripheral oedema
• Sepsis
• Skin reactions
• Taste altered
• Thrombocytopenia
• Vomiting
• Weight decreased

Interactions

• Anthracyclines: Severe (increases risk of cardiotoxicity)
• Anthracyclines + trastuzumab-emtansine: Severe (increases risk of cardiotoxicity)
• Cobicistat + trastuzumab-emtansine: Severe (increases exposure)
• Idelalisib + trastuzumab-emtansine: Severe (increases exposure)
• Clarithromycin + trastuzumab-emtansine: Severe (increases exposure)
• Anthracyclines + trastuzumab-deruxtecan: Unknown (increases risk of cardiotoxicity)

Precautions

• Monitor for cardiac function before each treatment cycle and throughout therapy
• Females of childbearing potential should use effective contraception during treatment and for at least 3 months after last treatment

Pregnancy

Use is not recommended during pregnancy. If exposed, monitor the infant for B-cell depletion.

Breast-feeding

It is not known if trastuzumab is excreted in human milk. Caution should be exercised.

Dosage

Children: Refer to specific drug information for paediatric dosing guidelines, as this will also vary.

Adults: Refer to specific drug information for dosing guidelines, as this will vary widely.

Mechanism of action

The mechanism of action for 'alfa' cannot be defined without specific identification of the drug. Each compound named 'alfa' will have distinct mechanisms, typically involving receptor interaction, enzyme inhibition, or modulation of physiological pathways.

Pharmacodynamics

Pharmacodynamics will vary widely depending on the specific agent referred to as 'alfa'. Generally, pharmacodynamics describes how a drug affects the body, including its therapeutic effects, side effects, and the relationship between drug concentration and effect.

Pharmacokinetics

The pharmacokinetics of 'alfa' would also depend on the particular drug profile, including absorption, distribution, metabolism, and excretion (ADME). Parameters such as bioavailability, half-life, and clearance rates would need to be defined based on the specific agent.

Pregnancy

Consult healthcare provider for risk assessment.

Breast-feeding

Consult healthcare provider for risk assessment.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Rheumatoid arthritis
• Allergic diseases
• Ulcers
• Anemia

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

The exact actions of supplemental L-histidine are not fully understood, but it is postulated to have immunomodulatory and antioxidant properties. It serves as the precursor for histamine, which can enhance suppressor T cell activity and potentially down-regulate the production of reactive oxygen species in immune cells. This may confer benefits in conditions like rheumatoid arthritis, where oxidative stress is a concern.

Pharmacodynamics

L-histidine is abundant in hemoglobin and contributes to various bodily functions. It has been clinically associated with treating rheumatoid arthritis, allergic diseases, ulcers, and anemia. Deficiencies in L-histidine can lead to complications such as impaired hearing. Its metabolites, particularly histamine, exhibit immunomodulatory effects and antioxidant capabilities.

Pharmacokinetics

L-histidine is absorbed through the gastrointestinal tract, and its bioavailability can be influenced by dietary intake. Once ingested, it is incorporated into proteins and utilized in various metabolic pathways, including histidine biosynthesis and tRNA charging. The metabolism of L-histidine involves its conversion to histamine, which subsequently participates in numerous physiological processes.

Pregnancy

There is limited data on the use of L-histidine during pregnancy. Consult healthcare professionals.

Breast-feeding

Limited information is available on the excretion of L-histidine in human milk. Consult healthcare professionals before use.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

• L-histidine powder
• L-histidine capsules
• L-histidine tablets

Indications

• Methionine deficiency
• Hepatotoxicity prevention
• Cholesterol management

Mechanism of action

The mechanism of the possible anti-hepatotoxic activity of L-methionine is not entirely clear. It is thought that metabolism of high doses of acetaminophen in the liver leads to decreased levels of hepatic glutathione and increased oxidative stress. L-methionine serves as a precursor to L-cysteine, which has antioxidant properties and is a precursor to glutathione. The antioxidant activity of L-methionine and its metabolites likely contribute to its potential anti-hepatotoxic effects. Methionine also exhibits free-radical scavenging activity and chelating ability due to its sulfur content.

Pharmacodynamics

L-Methionine functions as a primary supplier of sulfur, which is essential for preventing hair, skin, and nail disorders. It aids in lowering cholesterol levels by enhancing the liver's production of lecithin, reducing liver fat, and protecting kidney function. Methionine acts as a natural chelating agent for heavy metals and helps regulate ammonia formation, contributing to ammonia-free urine and reduced bladder irritation. Furthermore, it influences hair follicles and promotes hair growth, in addition to its potential protective effects against hepatotoxins like acetaminophen.

Pharmacokinetics

Methionine is absorbed from the gastrointestinal tract and is distributed throughout the body, where it is utilized in protein synthesis and converted into other metabolites, such as S-adenosylmethionine and L-cysteine. The metabolism of methionine involves several pathways, including transsulfuration to cysteine and incorporation into proteins. The renal clearance of methionine is significant, as it is involved in the regulation of nitrogen balance and the formation of ammonia.

Adverse effects

• Nausea
• Vomiting
• Abdominal pain
• Allergic reactions

Precautions

• Use with caution in patients with liver disease
• Monitor for allergic reactions in sensitive individuals

Pregnancy

There is insufficient evidence to determine the safety of methionine during pregnancy. Consult a healthcare provider before use.

Breast-feeding

It is not known whether methionine is excreted in human milk. Caution is advised when administering to breastfeeding women.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral tablets
• Powder for oral solution

Dosage

Children: Refer to specific product information as dosages vary based on the formulation and indication.

Adults: Refer to specific product information as dosages vary based on the formulation and indication.

Mechanism of action

Monohydratea typically functions by providing increased solubility for other compounds, which facilitates their absorption in the gastrointestinal tract. This mechanism is particularly important for drugs that are poorly soluble in their anhydrous forms.

Pharmacodynamics

The pharmacodynamic profile of monohydratea is largely dependent on its role as a carrier for other active ingredients. It does not exhibit significant pharmacological activity on its own, but by improving the solubility and stability of co-administered drugs, it can enhance their therapeutic effects.

Pharmacokinetics

The pharmacokinetics of monohydratea is characterized by its rapid dissolution and subsequent absorption when administered orally. It is generally well-tolerated, with minimal systemic effects. The elimination of any active compounds associated with it follows standard metabolic and excretory pathways, typically involving renal clearance.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering to breastfeeding mothers, as it is unclear whether the drug is excreted in human milk.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Emulsifying agent in drug formulations
• Stabilizer for parenteral preparations
• Solubilizer for hydrophobic drug compounds
• Ingredient in topical formulations

Dosage

Children: Refer to specific product guidelines, as dosing varies based on formulation and intended use.

Adults: Refer to specific product guidelines, as dosing varies based on formulation and intended use.

Mechanism of action

Polysorbate functions primarily as an emulsifying agent. It reduces the surface tension between immiscible liquids, allowing them to mix more easily. This property is particularly useful in stabilizing emulsions and suspensions, facilitating the delivery of active pharmaceutical ingredients in various formulations.

Pharmacodynamics

Polysorbate does not exert pharmacological effects in the traditional sense, as it does not bind to specific receptors to elicit a physiological response. Instead, it plays a crucial role in modifying the physical properties of drug formulations, thereby enhancing drug delivery and absorption. Its ability to solubilize drugs enhances their bioavailability, particularly for poorly soluble compounds.

Pharmacokinetics

Polysorbate is generally considered to be non-toxic and is not absorbed to a significant extent when administered orally. It is metabolized by the liver and excreted primarily through the gastrointestinal tract. The pharmacokinetic profile may vary depending on the route of administration and the specific formulation in which it is used.

Adverse effects

• Allergic reactions
• Skin irritation
• Gastrointestinal disturbances

Precautions

• Use cautiously in patients with known allergies to polysorbates or related compounds
• Monitor for allergic reactions in susceptible individuals

Pregnancy

Polysorbate is generally considered safe for use during pregnancy, but consult with a healthcare provider for specific cases.

Breast-feeding

Polysorbate is considered safe during breastfeeding, but consult with a healthcare provider for individual advice.

Storage

Store at room temperature, away from direct sunlight and moisture.

Formulations

• Polysorbate 20
• Polysorbate 80

Indications

• Sweetening agent in food and beverages
• Ingredient in pharmaceutical formulations
• Source of quick energy

Dosage

Children: Refer to specific formulations and clinical guidelines for dosing, as sucrose does not have a standardized dosage. Typically used as needed for sweetening.

Adults: Refer to specific formulations and clinical guidelines for dosing, as sucrose does not have a standardized dosage. Typically used as needed for sweetening.

Mechanism of action

Sucrose is metabolized in the body to glucose and fructose, which are then used as energy sources. It does not have a specific pharmacological mechanism of action but contributes to energy metabolism via the glycolytic and citric acid pathways.

Pharmacodynamics

Upon ingestion, sucrose is hydrolyzed by the enzyme sucrase into its constituent monosaccharides, glucose and fructose. These monosaccharides are absorbed in the small intestine and enter the bloodstream, leading to a rise in blood glucose levels. This process provides a quick source of energy for cellular functions.

Pharmacokinetics

Sucrose is rapidly absorbed in the gastrointestinal tract after hydrolysis. Its absorption depends on the presence of sucrase in the intestine. Once in the bloodstream, glucose can be utilized by cells or stored as glycogen in the liver and muscles. The elimination half-life of sucrose itself is not well-defined as it is quickly broken down and utilized.

Pregnancy

Sucrose is generally regarded as safe during pregnancy when consumed in moderation as part of a balanced diet.

Breast-feeding

Sucrose is considered safe during breastfeeding when consumed in normal dietary amounts.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Oral solution
• Granules
• Tablets

Indications

• Neurodegenerative diseases
• Diabetes management
• Protective agent in stress conditions
• Potential use in rare metabolic disorders

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations, as pediatric dosing should be determined based on age, weight, and clinical condition.

Adults: Refer to the BNF for specific dosing guidelines as they may vary based on indication and formulation.

Mechanism of action

Trehalose acts by modulating cellular processes, particularly by stabilizing proteins and cellular structures under stress conditions. It enhances autophagy, a cellular degradation and recycling process, which plays a critical role in maintaining cellular homeostasis. The modulation of this pathway can lead to neuroprotective effects, making trehalose a compound of interest in neurodegenerative disease research.

Pharmacodynamics

Trehalose is believed to exert its effects by improving cellular resilience to stress and enhancing the clearance of misfolded proteins. It may also influence glucose metabolism and help maintain osmotic balance, reducing cellular damage in conditions such as diabetes and neurodegenerative diseases. The compound has shown promise in preclinical studies for its ability to improve cognitive function and protect against cellular injury.

Pharmacokinetics

Trehalose is absorbed in the intestine and metabolized primarily by trehalase enzymes. It has a relatively low bioavailability, and its metabolism can vary based on dietary intake and individual enzymatic activity. The pharmacokinetics of trehalose are influenced by its solubility and stability in aqueous environments, with a half-life that may vary depending on the dosage form and route of administration.

Mechanism of action

Since the actions of supplemental L-histidine are unclear, any postulated mechanism is entirely speculative. However, some facts are known about L-histidine and some of its metabolites, such as histamine and trans-urocanic acid, which suggest that supplemental L-histidine may one day be shown to have immunomodulatory and/or antioxidant activities. Low free histidine has been found in the serum of some rheumatoid arthritis patients. Serum concentrations of other amino acids have been found to be normal in these patients. L-histidine is an excellent chelating agent for such metals as copper, iron and zinc. Copper and iron participate in a reaction (Fenton reaction) that generates potent reactive oxygen species that could be destructive to tissues, including joints. L-histidine is the obligate precursor of histamine, which is produced via the decarboxylation of the amino acid. In experimental animals, tissue histamine levels increase as the amount of dietary L-histidine increases. It is likely that this would be the case in humans as well. Histamine is known to possess immunomodulatory and antioxidant activity. Suppressor T cells have H2 receptors, and histamine activates them. Promotion of suppressor T cell activity could be beneficial in rheumatoid arthritis. Further, histamine has been shown to down-regulate the production of reactive oxygen species in phagocytic cells, such as monocytes, by binding to the H2 receptors on these cells. Decreased reactive oxygen species production by phagocytes could play antioxidant, anti-inflammatory and immunomodulatory roles in such diseases as rheumatoid arthritis. This latter mechanism is the rationale for the use of histamine itself in several clinical trials studying histamine for the treatment of certain types of cancer and viral diseases. In these trials, down-regulation by histamine of reactive oxygen species formation appears to inhibit the suppression of natural killer (NK) cells and cytotoxic T lymphocytes, allowing these cells to be more effective in attacking cancer cells and virally infected cells.

Pharmacodynamics

Is found abundantly in hemoglobin; has been used in the treatment of rheumatoid arthritis, allergic diseases, ulcers and anemia. A deficiency can cause poor hearing.

Mechanism of action

The mechanism of the possible anti-hepatotoxic activity of L-methionine is not entirely clear. It is thought that metabolism of high doses of acetaminophen in the liver lead to decreased levels of hepatic glutathione and increased oxidative stress. L-methionine is a precursor to L-cysteine. L-cysteine itself may have antioxidant activity. L-cysteine is also a precursor to the antioxidant glutathione. Antioxidant activity of L-methionine and metabolites of L-methionine appear to account for its possible anti-hepatotoxic activity. Recent research suggests that methionine itself has free-radical scavenging activity by virtue of its sulfur, as well as its chelating ability. Amino acids are selected for protein synthesis by binding with transfer RNA (tRNA) in the cell cytoplasm. The information on the amino acid sequence of each individual protein is contained in the sequence of nucleotides in the messenger RNA (mRNA) molecules, which are synthesized in the nucleus from regions of DNA by the process of transcription. The mRNA molecules then interact with various tRNA molecules attached to specific amino acids in the cytoplasm to synthesize the specific protein by linking together individual amino acids; this process, known as translation, is regulated by amino acids (e.g., leucine), and hormones. Which specific proteins are expressed in any particular cell and the relative rates at which the different cellular proteins are synthesized, are determined by the relative abundances of the different mRNAs and the availability of specific tRNA-amino acid combinations, and hence by the rate of transcription and the stability of the messages. From a nutritional and metabolic point of view, it is important to recognize that protein synthesis is a continuing process that takes place in most cells of the body. In a steady state, when neither net growth nor protein loss is occurring, protein synthesis is balanced by an equal amount of protein degradation. The major consequence of inadequate protein intakes, or diets low or lacking in specific indispensable amino acids relative to other amino acids (often termed limiting amino acids), is a shift in this balance so that rates of synthesis of some body proteins decrease while protein degradation continues, thus providing an endogenous source of those amino acids most in need. /Protein synthesis/ The mechanism of intracellular protein degradation, by which protein is hydrolyzed to free amino acids, is more complex and is not as well characterized at the mechanistic level as that of synthesis. A wide variety of different enzymes that are capable of splitting peptide bonds are present in cells. However, the bulk of cellular proteolysis seems to be shared between two multienzyme systems: the lysosomal and proteasomal systems. The lysosome is a membrane-enclosed vesicle inside the cell that contains a variety of proteolytic enzymes and operates mostly at acid pH. Volumes of the cytoplasm are engulfed (autophagy) and are then subjected to the action of the protease enzymes at high concentration. This system is thought to be relatively unselective in most cases, although it can also degrade specific intracellular proteins. The system is highly regulated by hormones such as insulin and glucocorticoids, and by amino acids. The second system is the ATP-dependent ubiquitin-proteasome system, which is present in the cytoplasm. The first step is to join molecules of ubiquitin, a basic 76-amino acid peptide, to lysine residues in the target protein. Several enzymes are involved in this process, which selectively targets proteins for degradation by a second component, the proteasome. /Protein degradation/ Methionine dependence, the inability of cells to grow when the amino acid methionine is replaced in culture medium by its metabolic precursor homocysteine, is characteristic of many cancer cell lines and some tumors in situ. Most cell lines proliferate normally under these conditions. The methionine dependent t

Pharmacodynamics

L-Methionine is a principle supplier of sulfur which prevents disorders of the hair, skin and nails; helps lower cholesterol levels by increasing the liver's production of lecithin; reduces liver fat and protects the kidneys; a natural chelating agent for heavy metals; regulates the formation of ammonia and creates ammonia-free urine which reduces bladder irritation; influences hair follicles and promotes hair growth. L-methionine may protect against the toxic effects of hepatotoxins, such as acetaminophen. Methionine may have antioxidant activity.